NBNazife Şule Yaşar Bilge

Nazife Şule Yaşar Bilge

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nazife Şule Yaşar Bilge has a total of 274 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    The effect of pulmonary nodule presence on disease severity and course in ANCA-associated vasculitis: a multicenter cohort study

    by Ayşe Elif Boncukcuoğlu, Muhammed Faruk Kazanbaş, Akın Işık, Sevgi Bilen Ayhan, Meysere Nur Akuç, Burcu Ceren Ekti Uludoğan, Mehmet Ali Enlice, İzZet Selçuk Parlak, Esra Gemici, Ebru Aşıcıoğlu, et al.

  • İnflamatuvar Miyopatilerde Miyozit Spesifik Antikorlar ve Klinik Kullanımı: Tek Merkez Deneyimi

    by Mesut Ajder, Reşit Yıldırım, Burcu Ceren Uludoğan, Nilgün Kaşifoğlu, Nazife Şule Yaşar Bilge, Timuçin Kaşifoğlu

    Miyozit spesifik antikorlar (MSA), inflamatuvar miyozitleri sınıflandırmada, klinik seyir ve prognozu öngörmede son yıllarda artan sıklıkla kullanılmaktadır. Bu çalışmada merkezimizde takipli inflamatuvar miyopatili hastalar içerisinde miyozit spesifik antikoru çalışılmış hastaların demografik özellikleri, tanıları, klinik bulguları, laboratuvar verileri, antikor profilleri, enfeksiyöz komplikasyon ve malignite gelişimi ve mortalite verileri analiz edildi. Çalışmaya toplam 33 hasta dahil edildi (29 kadın, 4 erkek). Medyan yaş 52 yıl (15-72) ve medyan takip süresi 27 ay (2-250) olarak hesaplandı. Hastaların 15 (%45.4)’i dermatomiyozit tanılı idi. Hastaların 26’sında MSA pozitif saptandı. En sık pozitif saptanan antikorlar Jo-1 (%26,9) ve TIF-1 gamma (%23,1) idi. MSA pozitif inflamatuvar myopatili hastalarda konstitüsyonel semptomlar daha sık görülmekteydi (p:0,011). MSA alt gruplarına (Jo-1 ve diğerleri/ TIF-1 gamma ve diğerleri/ MDA-5 ve diğerleri) göre klinik bulgular değerlendirildiğinde; pulmoner tutulum ile Jo-1 pozitifliği (p<0,001) ve MDA-5 pozitifliği ile kalsinozis (p:0,018) arasında istatistiksel olarak anlamlı bir ilişki bulundu. Toplam 13 hastada infeksiyöz komplikasyonlar ve 3 hastada malignite gelişmişti (serviks, over ve kolorektal karsinom). Çalışmamızda MSA alt gruplarının sıklığı literatür ile benzerlik taşısa da genelleme yapabilmek için geniş hasta popülasyonunda yapılacak çalışmalara ihtiyaç vardır.

  • Open Access

    Clinical Features and Phenotypic Similarities of Patients with Familial Behçet’s Disease

    by Kerem Abacar, Ayşe Elif Boncukcuoğlu, Rabia Deniz, Burcu Ceren Uludogan, Dilara Kaş, Elifnur Alkan, Gamzenur Kaya, Tuğçe Bozkurt, Nazife Şule Yaşar Bilge, Cemal Bes, et al.

    Background: Behçet’s disease (BD) exhibits significant phenotypic diversity. The genetic basis of phenotypic variations in BD has not yet been elucidated. Based on the high frequency of familial BD, we aimed to analyze the familial aggregation of various manifestations of BD in this study. Methods: Patients with BD from 3 Turkish tertiary rheumatology outpatient clinics were evaluated. Demographic and clinical characteristics of the familial group with either a first- or second-degree relative with BD and the non-familial group were compared. Afterward, patients in the familial disease group for 5 years or longer were divided into 2: an “index patient” and a “first-degree relative patient” and the presence of BD manifestations were compared between these 2 groups. Results: We identified 864 BD patients (mean age (SD): 47.9 (12) years, disease duration (SD): 83.7 (65.3) months) with 251 (29.1%) having a BD family history. Genital ulcers (P =.002) and papulopustular lesions (P < .001) were detected more frequently in the familial group. Also in the familial group, statistically significant correlations were detected between the index patient and the first-degree relativepatient in terms of erythema nodosum-like lesions (r: 0.398, P: .016), pathergy test positivity (r: 0.561, P: .002), peripheral joint involvement (r: 0.563, P < .001) and vascular involvement (r: 0.408, P: .014). Conclusion: Familial BD may differ from sporadic BD. Additionally, erythema nodosum-like lesions, pathergy test positivity, and vascular and joint involvement may tend to show familial aggregation. Cite this article as: Abacar K, Elif Boncukcuoğlu A, Deniz R, et al. Clinical features and phenotypic similarities of patients with familial Behçet’s disease. Eur J Rheumatol. 2025, 12(2), 0116, doi: 10.5152/eurjrheum.2025.24116.


  • Open Access

    Real‐World Insights From Türkiye: Biologic DMARDs Usage in Spondyloarthritis Patients With Chronic Kidney Disease

    by Dilara Bulut Gökten, Mehmet Engin Tezcan, Burcu Yağız, Abdulsamet Erden, Gezmiş Kimyon, Nazife Şule Yaşar Bilge, Levent Kılıç, Belkıs Nihan Coşkun, Emine Duygu Ersözlü, Orhan Küçükşahin, et al.

    Aim: The objective was to evaluate biologic disease‐modifying antirheumatic drugs (DMARDs) and their side effects that hindered the continuation of treatment in a patient population diagnosed with spondyloarthritis (SpA) with a glomerular filtration rate (GFR) ≤ 60 mL/min, and to compare these side effects between patients with chronic kidney disease (CKD) and those without.Methods: This multicenter, observational cohort study utilized data from the TReasure database, which records SpA patients in a web‐based system across Türkiye. A total of 6052 patients being included. SpA patients were categorized into two main groups: non‐CKD patients and CKD patients. The clinical characteristics, disease activity, treatment options, drug retention rates, reasons for drug discontinuation, and types of adverse effects were compared between the groups.Results: Biologics prescription pattern varied between CKD and non‐CKD patients. Etanercept was prescribed more frequently (53.1%) in CKD patients. Regarding the number of side effects and drug discontinuations in CKD patients, no statistically significant differences were found between the non‐CKD and CKD groups for any of the bDMARDs (adalimumab, etanercept, golimumab, infliximab, ustekinumab, secukinumab, and certolizumab). No statistically significant differences were observed in the duration of drug retention based on CKD status for bDMARDs.Conclusion: This study offers preliminary evidence supporting the effective and safe use of bDMARDs in patients with SpA and CKD.


  • Open Access

    Are Male Patients with Behçet’s Disease Unlucky? : An Analysis of 506 Behçet Patients

    by Burcu Ceren Uludoğan, Mustafa Dinler, Reşit Yıldırım, Yasemin Sağlan, Nazife Şule Yaşar Bilge, Timuçin Kaşifoğlu

    Background Behçet's Disease (BD) is characterized by oral and genital ulcers, arthritis, skin manifestations, uveitis, gastrointestinal tract, and central nervous system involvement. Although it is known to be more severe in men, there are studies in the literature with conflicting results regarding gender and the distribution of clinical findings. This study aimed to examine the relationship between clinical findings and gender in BD patients and to compare our results with the literature. Methods 506 patients diagnosed with Behçet's disease were included in the study. Demographic data, laboratory, and clinical findings of the patients were obtained retrospectively from hospital records. The distribution of clinical findings according to gender was evaluated. Results A total of 280 males (55.3%) and 226 females (44.7%) were included in the study. There was no significant difference between male and female patients regarding age at diagnosis (p=0.662). Genital ulcer (47.6% vs 52.4%, p=0.011), superficial thrombophlebitis (20.9% vs 79.1%, p=0.002), uveitis (33.7% vs 66.3%, p=0.02), deep vein thrombosis (22.5% vs 77.5%, p=0.00) and pulmonary artery aneurysm (11.1% vs 88.9%, p=0.046) were more common in males. There was no significant difference between the sexes in other clinical findings, HLA B5, and pathergy positivity. Conclusion Gender impacts the clinical manifestations of BD and should be considered in patient follow-up. However, it is a heterogeneous disease, other factors may certainly affect the emergence of clinical findings.

  • Open Access

    Predicting extra-musculoskeletal and peripheral manifestations and their role on biologic treatment in patients with axial spondyloarthritis: TReasure experience

    by Sedat Kiraz, Servet Akar, İhSan Ertenli, Süleyman Serdar Koca, Emine Duygu Ersözlü, Gezmiş Kimyon, Hakan Emmungil, Recep Yılmaz, Askın Ateş, Nilufer Alpay Kanıtez, et al.

    Objectives: This study aimed to examine the frequency and associated factors of extra-musculoskeletal manifestations (EMMs) and peripheral manifestations in an axial spondyloarthritis (axSpA) cohort and their impact on the choice of first biologic treatment. Patients and methods: A total of 1,687 patients with axSpA (978 males, 709 females; mean age: 38.5±11 years) who started their first biologic disease modifying antirheumatic drug (bDMARD) were included from a national prospective database of TReasure between its inception and 2018-2021. Demographic and clinical characteristics, disease-related features, and treatment patterns were compared between patients with and without EMMs or peripheral involvement. Results: Of the patients, 1,283 had radiographic axSpA (r-axSpA), while 404 had nonradiographic axSpA (nr-axSpA). Acute anterior uveitis (AAU) was the most common (11.4%) EMM, and older age, female sex, human leukocyte antigen B27 (HLA-B27) positivity, and a lower Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score were associated with AAU. Female sex, methotrexate use, dactylitis, and higher Ankylosing Spondylitis Disease Activity Score (ASDAS)-serum C-reactive protein (CRP) scores were related to psoriasis (PsO). Inflammatory bowel disease (IBD) and PsO were negatively associated with HLA-B27 positivity. Enthesitis was the most frequent (28.2%) peripheral manifestations, and peripheral arthritis, dactylitis, and enthesitis were independent predictor of each other. In addition, dactylitis and peripheral arthritis were related to more frequent use of conventional disease modifying antirheumatic drugs. In addition, IBD history was associated with less frequent use of etanercept. Older age, less use of sulfasalazine, the absence of enthesitis, and lower Bath Ankylosing Spondylitis Functional Disease Index (BASFI) scores were associated with secukinumab use. Conclusion: Acute anterior uveitis was associated with HLA-B27 positivity, while PsO or IBD were negatively associated with HLA-B27 in patients with axSpA. Peripheral manifestations appeared to be related to each other. Among EMMs, we found that only IBD had an effect on the bDMARD preference.


  • Open Access

    Glucocorticoid doses according to tissue/organ involvement in ANCA-associated vasculitis

    by Nazife Şule Yaşar Bilge

    Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides (AAV) are a group of disorders that include granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), renal-limited vasculitis, and eosinophilic granulomatosis with polyangiitis (EGPA). Infections and cardiovascular diseases are the main causes of death in patients with AAV. New treatment regimens with low-dose glucocorticoidsare proposed to reduce the frequency of side effects. Studies related to the use of glucocorticoids in AAV patients were searched in the literature and results were summarized. Low-dose steroid protocols are not inferior to standard dose treatment and have fewer side effects. Although their effectiveness appears to be similar and their side effects appear to be less, the long-term results of low-dose regimens should also be evaluated.New studies are needed for alternative treatment regimens.

  • DIGITAL ULCERATION FOLLOWING GEMCITABIN PLUS CISPLATIN CHEMOTHERAPY IN A SYSTEMIC SCLEROSIS PATIENT WITH LUNG ADENOCARCINOMA

    by Hüseyin Oruç, Reşit Yıldırım, Nazife Şule Yaşar Bilge, Timuçin Kaşifoğlu

    Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by fibrosis and vascular dysfunction in the skin and visceral organ systems. Digital ulceration is one of the major cause of morbidity. Although its pathogenesis has not been fully elucidated, structural and functional disturbances in small vessels are considered one of the major mechanisms. While cold exposure is considered the most important inciting factor for the development of digital ulceration, drugs and physical trauma are other described triggering factors. Herein, we report a case with SSc diagnosis who developed digital ulcers following gemcitabine and cisplatin chemotherapy for lung adenocarcinoma.

  • Open Access

    The Effect of Lupus on Pregnancy and the Foetus: Should we really be Worried? A Single-Centre Retrospective Study

    by Emre Kaan Cadir, Nazife Sule Yasar Bilge, Muzaffer Bilgin, Timucin Kasifoglu

    Systemic Lupus Erythematosus (SLE), is common in women of childbearing age and is associated with obstetric complications. The aim of this study was to evaluate the course of pregnancy and its results in SLE patients with a history of pregnancy. Pregnant patients with SLE who applied to the Rheumatology outpatient clinic of between 2010 and 2020 were retrospectively screened. Fifty-five pregnancies of 31 SLE patients were included in the study. Spontaneous abortion was observed in 27.3% (n:15) and foetal loss in 18.2% (n:10). Neonatal loss or maternal death was not observed in any of the patients. The rate of patients with renal involvement was 34.5% (n:19), and the rate of exacerbation was higher in pregnant women with kidney involvement (26% vs 0% (p:0.006)). Antiphospholipid antibody syndrome (APS) was present in 32.7% (n:18) of the cases, and there was a history of foetal loss before diagnosis in 50% (n:9) of the cases with APS. The foetal loss was seen only in pregnant women with APS (55.6% (n:10) vs. 0% (n:0) (p<0.001)). Six (10.9%) of 55 pregnancies in our study were unplanned pregnancies. Of these, five resulted in abortion. Exacerbation was observed in 3 of the unplanned pregnancies. Pregnancy complications were significantly lower in patients who were in remission since contraception. Exacerbations were more common in unplanned pregnancies and in patients with renal involvement. The presence of APS was associated with increased pregnancy morbidity.


  • Open Access

    Romatolojide Güncel Tedaviler

    by Duygu Kurtuluş, Ali Nail Demir, İsMail Uçar, Önay Gerçik, Hüseyin Ali Öztürk, Alper Yıldırım, Neslihan Gökçen, Zeynep Kaya, Meryem Can, Zübeyde Uğurlu, et al.

    Analjezikler, Non-Steroid Anti-İNFLAMATUAR İlaçlar ve Kortikosteroidler Duygu KURTULUŞ Biyolojik Olmayan Hastalık Modifiye Edici Antiromatizmal ilaçlar Ali Nail DEMİR Romatolojide Biyolojik Tedavi Ajanları İsmail UÇAR İmmunsupresifler ve Diğer İlaçlar Önay GERÇİK Romatolojide İntravenöz İmmünoglobulin Uygulamaları Hüseyin Ali ÖZTÜRKAlper YILDIRIM Romatolojide Plazmaferez Uygulamaları Alper YILDIRIM Erken Artrit ve Palindromik Romatizma: Güncel Tedavi Neslihan GÖKÇEN Romatoid Artrit: Güncel Tedavi Zeynep KAYA Meryem CAN Romatoid Artritte Ekstra-Artiküler Tutulum Tedavisi Zübeyde UĞURLU Atalay DOĞRU Tekrarlayıcı Seronegatif Pİtting Ödemli Simetrik Sinovit (R3SPE) Sendromu Tedavi Yönetimi Berkan ARMAĞAN Erişkin Başlangıçlı Still Hastalığına Güncel Yaklaşım Ahmet KOR Şükran ERTEN Enfeksiyöz Artritler: Bakteriyel Artritler, Lyme Artriti, Viral Artritler, Mikobakteriyel, Brucella, Fungal Ve Parazitik Artritler: Güncel Tedavi Fatma TUNCER KURU Ankilozan Spondilit ve Non-Radyografik Aksiyel Spondiloartrit: Güncel Tedavi Dilek SOLMAZ Periferik Spondiloartrit: Güncel Tedavi Fatih SARITAŞ Psöriatik Artrit: Güncel Tedavi Selda ÇELİK Enteropatik Artrit Tedavisi Mete PEKDİKER Reaktif Artrit: Güncel Tedavi Özgül SOYSAL GÜNDÜZ Jüvenil İdyopatik Artrit Tedavisinde Güncel Yaklaşımlar Kenan BARUT Elif KILIÇ KÖNT Özgür KASAPÇOPUR Sistemik Lupus Eritematozusda Güncel Tedavi Hamide Kart KÖSEOĞLU Sjögren Sendromunda Güncel Tedavi Yaklaşımları Pınar TALU ERTEN Antifosfolipid Sendromu Tedavisi Pınar AKYÜZ DAĞLI Ahmet OMMA Gebelikte Sistemik Lupus Eritematozus ve Antifosfolipid Antikor Sendromu: Güncel Tedavi Senar ŞAN Ayten YAZICI Kutanöz Lupus Eritematosus: Güncel Tedavisi Tuğba TEHÇİ Sistemik Skleroz Tedavisi Yasemin YALÇINKAYA Raynaud Fenomeninin Güncel Tedavisi Duygu TEMİZ KARADAĞ İdiopatik İnflamatuar Myopati Güncel Tedavi Figen TARHAN Anti-Sentetaz Sendromu Emel GÖNÜLLÜ Mix Konnektif Doku Hastalığında Güncel Tedavi İpek TÜRK Undiferansiye Bağ Dokusu Hastalığı ve Overlap Sendromlar Güncel Tedavi Derya KAŞKARİ Poliarteritis Nodosa Güncel Tedavisi Esra KAYACAN ERDOĞAN Dev Hücreli Arterit ve Polimyaljiya Romatika Tedavisi Vedat GERDAN Granülomatöz Polianjiitis’te Güncel Tedavi Özlem DOĞAN AĞBUGA Diğer Anca İlişkili Vaskülitlerde Güncel Tedavi Emrah KOÇ Takayasu Arteriti Güncel Tedavisi Sema KAYMAZ TAHRA Fatma ALİBAZ ÖNER Klinik Tutulumlara Göre Behçet Hastalığında Güncel Tedavi Yüksel MARAŞ Kawasaki Hastalığı Güncel Tedavi Rabia Miray KIŞLA EKİNCİ İmmun Kompleks Küçük Damar Vaskülitlerinde Güncel Tedavi Elif EDİBOĞLU Sarkoidoz: Güncel Tedavi Müge AYDIN TUFAN Relapsing Polikondrit Suade Özlem BADAK IgG4 İlişkili Hastalık: Güncel Tedavi Nazife Şule YAŞAR BİLGE Timuçin KAŞİFOĞLU Ailevi Akdeniz Ateşi: Güncel Tedavi Zeynep TOKER DİNÇER Serdal UĞURLU Henoch Schönlein Purpurası (HSP) Özge Altuğ GÜCENMEZ FMF Dışı Otoenflamatuar Hastalıklar: Güncel Tedavi Amra ADROVİÇ Mehmet YILDIZ Özgür KASAPÇOPUR Otoinflamatuar Hastalıklarda Aa Amiloidoz Güncel Tedavi Safiye BAKKALGerçek CAN Gut: Güncel Tedavi Gezmiş KİMYON CPPD Güncel Tedavi Fatih Necip ARICI Alper YILDIRIM Konnektif Doku Hastalığı İlişkili Pulmoner Arteriyel Hipertansiyon Tedavisi Alper SARI Romatolojik Hastalıklarda İnterstisyel Akciğer Hastalığı: Güncel Tedavi Zevcet YILMAZ Romatolojik Hastalıklarda Aşılama Mehmet Ali AŞIK Gebe, Emziren Ve Gebelik Planı Olan Romatoloji Hastalarında Paternal ve Maternal İlaç Kullanımı Sercan GÜCENMEZ